Navigation Links
ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
Date:1/17/2008

MOUNTAIN VIEW, Calif., Jan. 17 /PRNewswire/ -- ChemoCentryx, Inc. today announced the appointment of Edward E. Penhoet, Ph.D., to the company's Board of Directors. Dr. Penhoet is recognized for his 25 years of leadership and contributions in the public and private sectors of the life sciences industry, including as co-founder and Chief Executive Officer of Chiron Corporation (now Novartis).

Dr. Penhoet is currently the President of the Gordon and Betty Moore Foundation, overseeing the philanthropic activities of the Foundation since 2004. Dr. Penhoet has also held the position of Director with Alta Partners, a venture capital partnership investing in life science companies, since 2000. From 1998 to 2002, he served as Dean of the School of Public Health at the University of California, Berkeley. In 1981, Dr. Penhoet co-founded Chiron Corporation and served as its Chief Executive Officer until 1998. Prior to founding Chiron, he was a faculty member of the Biochemistry Department of U.C. Berkeley. Dr. Penhoet also serves as the Vice Chairman of the Independent Citizen's Oversight Committee of the California Institute for Regenerative Medicine which was created by the passage of Proposition 71, also known as the stem cell initiative.

A member of the Institute of Medicine of the National Academies of Sciences and a member of the American Society of Biological Chemists, Dr. Penhoet has co-authored more than 50 scientific articles and papers. In addition to ChemoCentryx, he serves as a Director of Zymogenetics, Scynexis, Metabolex and Renovis, Inc.

Dr. Penhoet earned his A.B. in biology from Stanford University, and his Ph.D. in biochemistry from the University of Washington. He was a post-doctoral fellow at the University of California, San Diego.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a complex network of chemokine molecules, or ligands, and receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a multi-national clinical trial, called PROTECT-1, for patients with moderate-to-severe Crohn's disease. For more information, please refer to http://www.chemocentryx.com.

ChemoCentryx believes that certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include, but are not limited to (i) that ChemoCentryx anticipates incurring significant losses for the foreseeable future, (ii) dependence on the success of Traficet-EN(TM); (iii) delays in obtaining or a failure to obtain regulatory approval for product candidates, (iv) failure of any approved product to achieve significant commercial acceptance in the medical community or receive reimbursement by third-party payors, (v) the timing, success and cost of preclinical research and clinical studies, (vi) the timing, acceptability and review periods for regulatory filings, (vii) the availability of corporate partners, (viii) uncertainties relating to patent protection and intellectual property rights, (ix) the impact of competitive products and technological changes, (x) competition from other pharmaceutical or biotechnology companies, (xi) the availability of capital and the cost of capital, (xii) other vagaries in the biotechnology industry and (xiii) other risks. ChemoCentryx undertakes no obligation to update or revise any forward-looking statements to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
2. Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
3. LifeVantage Corporation Appoints Industry Veteran David Brown as President & CEO
4. Crdentia Appoints Debbie Griffith to Director of Business Development, Reporting Directly to CEO
5. WellPoint Appoints Brian A. Sassi as President and CEO of the Companys Consumer Business Unit
6. Digirad Corporation Board of Directors Appoints R. King Nelson Chairman
7. Thermage, Inc. Appoints John F. Glenn as Chief Financial Officer
8. China Sky One Medical Appoints Independent Auditor
9. Genstar Capital Appoints Mark Hanson to Managing Director
10. Casey Family Programs Appoints New Board Members
11. Casey Family Programs Appoints Dr. America Bracho as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social Media: ... journal chronicling the writer’s path toward true communion with God. “Finding Christ Through ... is the creation of published author Lea Michelle Johnson, a follower of Christ, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “Vintage and ... a retired minister and college Bible teacher residing in North Carolina with his wife, ... who have blessed them with six grandchildren. David is also the author of “Shadow ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story ... fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” ... passion for writing, especially about truth and human behavior. , Published by Christian Faith ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates for ... on a review of GPA and SAT/ACT requirements at 221 institutions in 25 states, ... that this higher bar should be set by states, by the Council for the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $3.5 ... estimates and forecasts for all the given segments on global as ...
(Date:3/23/2017)... , March 23, 2017 The ... ageing population, increasing diabetic population, accelerating economic growth and increasing ... this industry are higher life expectancy of ESRD patients, rising ... emerging markets. However, the expansion of the market is hindered ... ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a multi-modal ... end-to-end supply chain management firm with expertise serving clients ... Solutions Rick Zaffarano was named a 2017 ... Supply Chain by the only publication exclusively dedicated to ... supply chain. "Rick has brought to Transportation ...
Breaking Medicine Technology: